TY - JOUR
T1 - Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma
AU - Pophali, Priyanka A.
AU - Thanarajasingam, Gita
N1 - Funding Information:
Funding sources: Dr G. Thanarajasingam receives grant funding from a Mayo Clinic Center for Clinical and Translational Science KL2 Mentored Career Development Award, which is funded by the National Center for Advancing Translational Science (NCATS), US National Institutes of Health (NIH) (KL2 TR002379).
Funding Information:
Funding sources: Dr G. Thanarajasingam receives grant funding from a Mayo Clinic Center for Clinical and Translational Science KL2 Mentored Career Development Award, which is funded by the National Center for Advancing Translational Science (NCATS) , US National Institutes of Health (NIH) ( KL2 TR002379 ).
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/10
Y1 - 2020/10
N2 - Mantle cell lymphoma (MCL) is a unique lymphoma that is heterogeneous in its clinical course, and lacks consensus treatment approaches. It is often treated with immunochemotherapy at diagnosis and chronic therapies in relapse. Despite significant advances in therapy, MCL remains incurable. Maintaining patients’ health-related quality of life (HRQOL) is an important treatment goal. Assessment of HRQOL elucidates the impact of an illness and its treatment on patients’ lives. This review highlights the relevance of HRQOL assessment in MCL, evaluates existing evidence, current knowledge gaps and challenges in HRQOL assessment, and defines future directions for improving HRQOL evaluation in MCL patients.
AB - Mantle cell lymphoma (MCL) is a unique lymphoma that is heterogeneous in its clinical course, and lacks consensus treatment approaches. It is often treated with immunochemotherapy at diagnosis and chronic therapies in relapse. Despite significant advances in therapy, MCL remains incurable. Maintaining patients’ health-related quality of life (HRQOL) is an important treatment goal. Assessment of HRQOL elucidates the impact of an illness and its treatment on patients’ lives. This review highlights the relevance of HRQOL assessment in MCL, evaluates existing evidence, current knowledge gaps and challenges in HRQOL assessment, and defines future directions for improving HRQOL evaluation in MCL patients.
KW - Adverse events
KW - Chronic therapy
KW - HRQOL
KW - Mantle cell lymphoma
KW - Patient-reported outcomes
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=85089108729&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089108729&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2020.06.011
DO - 10.1016/j.hoc.2020.06.011
M3 - Review article
C2 - 32861290
AN - SCOPUS:85089108729
SN - 0889-8588
VL - 34
SP - 971
EP - 982
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 5
ER -